Analyst Sees Positive Outlook For Cabaletta Bio: Sees Promise In CAR-T Therapy Approach
Portfolio Pulse from Vandana Singh
Guggenheim Securities has initiated coverage of Cabaletta Bio Inc (CABA) with a Buy rating and a price target of $34. The positive outlook is based on the development of its CD19 CAR-T cell therapy CABA-201, currently in development for lupus and myositis. The company has successfully pivoted to treating a new disease using a well-established approach. CABA shares are up 11.90% at $13.99.
July 18, 2023 | 6:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cabaletta Bio Inc's stock is likely to see positive movement due to Guggenheim Securities' Buy rating and a price target of $34. The company's promising CD19 CAR-T cell therapy CABA-201 is currently in development for lupus and myositis.
The positive outlook from Guggenheim Securities, a reputable financial services firm, is likely to boost investor confidence in Cabaletta Bio Inc. The company's promising CD19 CAR-T cell therapy CABA-201, currently in development for lupus and myositis, further strengthens its position in the market. This combination of factors is likely to drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100